REGENERON PHARMACEUTICALS, INC. (REGN)

Every figure this model derived for REGN, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 920,900,000 PaymentsToAcquireProductiveAssets 2026-06-30
cash 7,994,600,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 18,446,000,000 AssetsCurrent 2026-06-30
current liabilities 5,530,600,000 LiabilitiesCurrent 2026-06-30
equity 31,711,400,000 StockholdersEquity 2026-06-30
interest expense 55,400,000 InterestExpenseNonoperating 2026-06-30
ocf 4,681,300,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 15,534,700,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 986,700,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up REGN on one particular measure came for.

RatioValue
cash operating margin34.49
current ratio3.81
current ratio reported3.34
deferred revenue growth42.1
dilution pct-5.65
ebit cagr-5.82
ebit yoy0.06
ev ebit20.9
ev owner earnings28.96
ev sales5.17
fcf margin24.21
growth cv2.34
interest cover69.37
operating margin24.74
owner earnings margin17.85
revenue growth9.29
revenue growth per share15.84
roic11.49
rule of 4034.03
sbc pct revenue6.35

What to be careful about

What this model itself distrusts about REGN's figures. Written by the derivation as it ran, not added afterwards.